Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136489 | 0.79 | SMN1; SMN2 (0.46) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL19668789 | 0.79 | KMT2A (0.42) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL236974 | 0.76 | KDM4A (0.45) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL11510201 | 0.76 | MAPK1 (0.43) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL11582679 | 0.76 | SMN1; SMN2 (0.52) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL244872 | 0.76 | LMNA (0.44) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL14007393 | 0.74 | NPC1 (0.52) | SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL24610231 | 0.73 | FCGR1A (0.43) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL21849228 | 0.73 | GRN (0.45) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL21217389 | 0.73 | ALDH1A1 (0.46) | MAPK1SMN1; SMN2CYP1A2CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | MAPK1 592/4885SMN1; SMN2 2663/4885CYP1A2 3467/4885 |
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | PINK1, ATG7, ADRM1 | MAPK1 2124/4885SMN1; SMN2 1999/4885CYP1A2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.